Johnson and Johnson sales hit by tough retail environment

By Simon Pitman

- Last updated on GMT

Leading pharmaceutical and personal care player Johnson & Johnson has been hit hard during its second quarter by the global economic recession.

Sales for the quarter fell by a total of 7.4 percent, down from $16.45bn in the corresponding period last year, to reach $15.24bn.

The fall in sales meant that revenue fell by 3.6 percent, down from $3.33bn to $3.32bn, a figure that beat Wall Street analysts’ expectations.

The company said it had helped to cushion the big fall in sales by cutting back spending on sales, administration and research by approximately 13 percent, at the same time as shaving 6 percent off production costs.

Pharmaceuticals suffer from patent problems

Breaking the sales revenue down the company’s mainstay pharmaceutical business saw sales slide by 13.3 percent to reach $5.50bn, a figure that was impacted by both negative currency impact and the loss of two medicine patent protections.

The loss of the patents was estimated to have impacted results during the quarter by at least $1bn.

Consumer sales, which encompasses personal care brands such as Listerine and J&J baby care products, faired better, with quarterly sales falling by 4.5 percent, down from $4.04bn in the corresponding quarter last year, to reach $3.85bn.

A difficult year for the company

Sales of medical devices, the company’s third division, fell by 3.1 percent during the quarter to reach $5.9bn.

“This was one of the most difficult years in our history,”​ said Dominic Caruso, company CFO during a conference call to analysts about the results.

William Weldon, CEO, said that the company had delivered solid operational results “in light of the significant impacts of patent expirations and the economic environment.”

Related topics: Business & Financial

Related news

Show more

Follow us

Featured Events

View more

Products

View more

Webinars